Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Outset Ventures, the Auckland-based venture firm and incubator that spun out deep tech unicorns like Rocket Lab and LanzaTech ...

Complete Zealand Pharma A/S ADR stock information by Barron's. View real-time ZLDPY stock price and news, along with industry-best analysis.

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Roche plans to invest nearly $300 million to build a new Chinese plant to produce Vabysmo. China's Hengrui Pharma is looking to raise up to $1.27 billion in its Hong Kong IPO. And more.